NeoGenomics Inc (NEO)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	538,198	537,475	536,755	536,037	535,322	534,609	533,898	533,189	532,483	531,779	531,077	530,378	168,120	166,440	164,544	90,605	91,829	93,027	94,250	90,995
Total stockholders’ equity	US$ in thousands	941,537	947,428	956,192	974,462	998,023	1,012,990	1,043,520	1,075,000	1,108,280	1,137,240	1,148,360	843,714	694,294	666,363	654,229	505,043	507,408	497,007	489,734	323,848
Debt-to-equity ratio		0.57	0.57	0.56	0.55	0.54	0.53	0.51	0.50	0.48	0.47	0.46	0.63	0.24	0.25	0.25	0.18	0.18	0.19	0.19	0.28

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $538,198K ÷ $941,537K
= 0.57

The debt-to-equity ratio of Neogenomics Inc. has been relatively stable over the past eight quarters, ranging from 0.50 to 0.57. This ratio indicates the proportion of the company's total liabilities to its total shareholders' equity. A higher ratio typically suggests that the company has more debt relative to its equity, which may indicate higher financial risk.

In the case of Neogenomics Inc., the increasing trend in the debt-to-equity ratio from Q1 2022 to Q4 2023 indicates a growing reliance on debt to finance its operations or expansion. However, the ratio has remained within a reasonable range for the industry and does not raise immediate concerns about the company's financial strength.

Investors and stakeholders should continue to monitor this ratio in future periods to ensure that Neogenomics Inc. maintains a healthy balance between debt and equity to support sustainable growth and financial stability.